The problem of interpreting missense mutations of disease-causing genes is an increasingly important one. Because these point mutations result in altering only a single amino acid of the protein product, it is often unclear whether this change alone is su cient to cause disease. We propose a Bayesian approach that utilizes genetic information on a ected relatives in families ascertained through known missense mutation carriers. This method is useful in evaluating known disease genes for common disease phenotypes, such as breast cancer or colorectal cancer. The posterior probability that a missense mutation is disease causing is conditioned on the relationship of the relatives to the proband, the population frequency of the mutation, and the phenocopy rate of the disease. The approach is demonstrated in two cancer datasets: BRCA1 R841W and APC I1307K. In both examples, this method helps establish that these mutations are likely to be disease causing, with Bayes factors in favor of causality of 5:09 and 66:97 respectively, and posterior probabilities of :836 and :985. We also develop a simple approximation for rare alleles and consider the case of unknown penetrance and allele frequency.
Introduction
The commitment of the genetics research community to map the human genome and identify disease causing genes has been successful in advancing our knowledge in a number of areas, such as molecular technology leading to more rapid cloning and sequencing of genes (Guyer and Collins, 1995; Savill, 1997; Schuler et al., 1996) . These major advances have opened other important areas of investigation, including biochemical mechanisms for disease, and genetic epidemiologic implications of newly discovered genes in patients and populations (Ellsworth et al., 1997) .
Of major importance is the interpretation of kinds of mutations that occur in genes and whether these may be involved in causation of disease (Cooper and Krawczak, 1993) . It is widely accepted that mutations that result in frameshifts (insertions or deletions) can signi cantly alter the protein product, as can point mutations that result in splice site alterations or stop codons (nonsense mutations). A problematic type of point mutation is one that results in a substitution of one amino acid for another (missense mutations). These amino acid substitutions can be disease causing if they a ect an important functional region of the protein. A well-known example is the substitution of valine for glutamic acid in the |globin gene at the sixth codon, which results in an abnormal hemoglobin that is less soluble in deoxygenated blood, the basic biochemical defect in sickle cell anemia.
Alternatively, an amino acid substitution may occur in a less critical or conserved region of the protein, and be tolerated, such that it results in an isoform of the protein, and genetically is interpreted as an allelic variant or possible polymorphism.
With the identi cation of disease causing genes, a major challenge to molecular geneticists is detection and characterization of mutations in a ected persons (Cotton, 1997).
The de nitive methodology is DNA sequencing, which will identify point mutations, including missense mutations. The interpretation of a missense mutation is often inconclusive as to whether it is disease-causing. In particular, when the mutation is frequent and carriers exhibit lower penetrance, it poses a greater challenge because one could argue 1 that it is a polymorphism.
We present a method that utilizes a Bayesian approach in families with multiple a ected persons to establish statistically whether a missense mutation in an autosomal dominant gene is disease causing. We apply this method to published data on a missense mutation of the APC gene in familial colon cancer (Laken et al., 1997 ) and a missense mutation of BRCA1 in hereditary breast cancer (Barker et al., 1996) .
Methods

Study Design
We propose a study design based on testing a ected relatives of probands who are known to be carriers of the missense mutation. This design is e cient and provides meaningful information about the association when there is good a priori information about the rate of sporadic disease in the population and about the population frequency of the mutation. If the missense mutation is not disease-causing, we expect to observe a proportion of positive a ected relatives that is simply dictated by the degree of relationship between the relatives in the sample and the proband. For example, among rst-degree relatives of heterozygous carrier probands of a rare mutation, we would expect about one half to be carriers. If the mutation is disease-causing, we expect to see an increased proportion, beyond one half, depending on the penetrance and the phenocopy rate. Our approach quanti es how many more to expect and weighs the evidence in favor of causality.
In addition to its practical and ethical advantages, a design based on testing only a ected relatives can be statistically e cient when reliable information about phenocopy rates is available. Swift et al studied a simpler design where a single a ected relative per proband is tested, and developed a large sample approximation to the con dence interval on the odds ratio of genotype given disease status. They also compared the statistical e ciency of a ected-only designs to that of case-control designs where una ected relatives are also tested, and concluded that if the disease incidence among non-carriers is known with reasonable accuracy, testing only a ected is substantially more e cient. Although our design is more general, their overall conclusions about e ciency are likely to be applicable here.
Sampling Distributions
We consider an autosomal dominant gene and focus on a single, potentially disease-causing allele (i.e. a missense mutation in a disease-causing gene). We assume that the allele frequency in the population is known, and we denote this by p, with 1 ? p = q. We also assume that the rate of disease among noncarriers (phenocopy rate) and the penetrance among carriers are known. We de ne the penetrance as = PfDiseasejAAg = PfDiseasejAag and the phenocopy rate as ' = PfDiseasejaag. We are interested in whether the allele is disease-causing: that is, in whether carriers of the allele are at increased risk. The presence of a causal e ect is denoted by the variable C, with C = 1 if the disease is caused by the mutation, C = 2 if not. So C = 1 corresponds to > ', while C = 2 corresponds to = '. The Appendix extends our approach to the case of unknown reduced penetrance and unknown allele frequency, with known rate of disease for the overall population.
To assess the presence of a causal e ect, we compute the Bayes factor for C = 1 versus C = 2 and the a posteriori probability that the allele is disease-causing, given the observed mutation test results in one or more pedigrees. If the penetrance, prevalence and phenocopy rate are known, the Bayes factor is simply the ratio of the likelihoods of the observed testing results under the two hypotheses. But using a Bayesian approach, extensions to unknown penetrance, prevalence, and phenocopy rate are straightforward.
For K probands, with genotypes g 01 ; : : : ; g 0K , where g 0k is either AA or Aa, and is xed by design, we have corresponding n k a ected relatives who are tested for the same mutation. The genotype of relative i of proband k is g ik , and can be AA, aa or Aa. The calculations are also conditioned on the relationship with the proband. To keep the notation concise we refer to the vector of the genotypes for the relatives of proband k as g k = (g 1k ; : : : ; g n k k ).
Because of the study design, all probabilities are implicitly conditional on the proband's genotype, on the relative being a ected, and on his/her degree of relationship with the proband.
We begin by considering the contribution of a single family in the sample. To evaluate this, we need to be able to evaluate the probabilities PfObserved genotypes of relativesjCg for all possible combinations of observed genotypes and C. If the mutation is not disease-causing (C = 2), the conditional probability of observed genotypes of relatives in family k is non-causal;k Pfg k jg 0k ; C = 2g = Pfg k jg 0k g;
(1) because a ected status does not carry any information about genotype probabilities.
Pfg k jg 0k g depends on the allele frequency p and also on the degree of relationship with the proband, which is not explicitly incorporated in the notation, but is considered in the calculation, and it can be determined simply based on the degree of relationship with the proband, using standard conditional probability arguments (Elandt-Johnson, 1971 ). and so forth. A general algorithm is presented by Li and Sacks (1954) . The software package LINKAGE (Laboratory of Statistical Genetics, Rockefeller University, 1998) can be used to automate these calculations.
If the mutation is disease-causing (C = 1), the expected fraction of carriers among a ected relatives is higher than if it is not disease-causing. Conditional on a genotype vector g k with n aa k relatives with aa genotype, and assuming that the disease outcomes of relatives are independent given their genotypes, the probability that all relatives have disease is ' n aa k n k ?n aa k . Using the genotype probabilities Pfg k jg 0k g as priors, we can determine genotype probabilities under C = 1 via Bayes' rule. For the C = 1 case, the probability of the observed genotypes of relatives in family k is causal;k = Pfgjg 0k ; C = 1g = Pfg k jg 0k g' n aa k n k ?n aa k P g Pfgjg 0k g' n aa g n k ?n aa g ; (2) where P g ranges over all 3 k possible genotype combinations, and n aa g is the number of aa elements in the vector g. In practice, the number of terms in the summation at the denominator can be reduced by factoring terms that lead to the same value of n aa g . For example, for a proband with one sibling who is Aa, we have When the disease has a variable age of onset, and age-of-onset data about relatives are available, and ' should be speci ed in terms of age-speci c survival contributions. This would entail taking each subject's age into account. However, by rewriting expression (2) as causal;k = Pfg k jg 0k g ' n aa k P g Pfgjg 0k g ' n aa g ; (3) it can be seen that causal;k depends on and ' only via their ratio, and therefore is valid as long as the ratio of the penetrance to the phenocopy rate remains constant with respect to age. It is possible to carry out an age-dependent analysis along the lines of the approach described here. However, this requires either a large number of observations or good a priori knowledge of the penetrance function for the mutation under consideration. These were not available in the applications considered in this paper.
Probability of a disease-causing e ect
We can now evaluate the probability of a causal e ect conditional on the observed mutation tests in the a ected relatives (Data). Because the families can be considered independent, in our case
non-causal;k so that the Bayes factor in favor of the hypothesis of causality is
Using expressions (1) and (2) and algebraic manipulation we can express the Bayes Factor simply in terms of the genotype coe cients and the penetrance-to-phenocopy-rate ratio:
This incorporates the dependence among relatives of the same proband and the possibility that there is more than one copy of the mutated allele in the same family.
Using Bayes rule, which states PfC = 1jDatag = PfC = 1gP fDatajC = 1g PfC = 1gP fDatajC = 1g + PfC = 2gP fDatajC = 2g ; (6) and denoting by O = PfC = 1g=P fC = 2g the a priori odds in favor of causality, the posterior probability of causality is PfC = 1jDatag = OB OB + 1 :
The choice of a priori odds can be important and must re ect the context of the analysis.
If the mutation was selected because it resides on a known disease-causing gene, the prior odds may be high, while when screening for disease causing mutation, a low, population based, prior probability of causality may be more appropriate. In any case, analysis of the Bayes factor gives a measure of the weight of evidence of the data in favor of the hypothesis that does not require specifying prior odds. Kass and Raftery (1995) give an in-depth discussion of interpretation and calibration of Bayes factors. A convenient option is assuming PfC = 1g = 1=2, which gives O = 1, that is even a priori odds to the hypothesis of causality.
3 Results
Familial Breast Cancer and BRCA1 R841W
We investigate the causality of the BRCA1 R841W mutation using two pedigrees from Barker et al., 1996 . The disease phenotype of interest is either breast or ovarian cancer.
There are K = 2 probands who have tested a ected relatives. Proband 1160 has one heterozygous sibling a ected with breast cancer, g 1 = g 11 = Aa. Proband 728 has two heterozygous siblings a ected with breast cancer. Thus g 2 = (g 12 ; g 22 ) = (Aa; Aa). We assume a phenocopy rate ' = :125, a penetrance = :85,indicated as plausible for other BRCA1 mutations (Ford and Easton, 1995) , and an allele frequency of p = 1=100. Evidence to estimate age-speci c penetrance for this speci c mutation is insu cient. Our calculations are based on assuming that the ratio =' of penetrance for carriers and noncarriers does not depend on age. We will later assess sensitivity to p and ='. Not all a ected family members are tested; we assume that the reason why they were not tested is unrelated to their genotype.
Using expressions (1) and (2) non-causal Mutations of the APC gene can be associated with increased risk of colorectal cancer and colorectal adenomas. We investigate the causality of mutation T to A at APC nucleotide 3920, using 8 pedigrees reported by Laken and colleagues (1997) . We used a disease rate of :2, based on clinical judgment, and an allele frequency of the mutation p of :036, based on Table 1 in Laken (1997); we estimated allele frequencies separately in the disease and control group and then combined using the postulated value of . Expressions (1) and (2) were computed for each proband. The results are summarized in Table 1 .
The resulting Bayes factor is 66:97 |strong evidence in favor of causality. The posterior probability under even prior odds is 0:985. The rare allele approximation discussed in the Appendix produces a Bayes factor of 194:90, leading to a posterior probability 0:995. Because the mutation is relatively common, the rare allele approximation does not work as well as in the breast cancer example. Also, using expression (12) leads to ignoring the dependence between proband's 8 sibling and her o spring and is therefore not appropriate in this case.
Following the development discussed in Appendix 1, we also conducted with unknown penetrance and allele frequency. We assumed that causality (C = 1) corresponds to > '
and we assume that if the mutation is indeed causal, then all values of are equally likely a priori. Regarding p, we used information from Table 1 in Laken et al (1997) to specify a prior on the fraction of carriers and then converted that into a distribution for p. To analyze the e ect of uncertainty about and p on the Bayes factor and posterior probability of C = 1, we rst computed the a posteriori probability distribution p( ; pjData; C = 1). This inference is conditional on the assumption of uninformative ascertainment, which may be violated in this data set. While inference on the penetrance and prevalence is not the focus of the methodology proposed here, incorporating uncertainty via p( ; pjData; C = 1) is an e ective strategy to make inferences about causality without relying on strong assumptions on and p. To illustrate the range of plausible values of , Figure 1 graphs the a posteriori probability distribution of conditional on p = :035. For the purpose of testing for causality, the important aspect of this distribution is that it assigns very low probability to values close to the phenocopy rate and high probability to values far away from it. So even though the actual magnitude of is not accurately estimated, reliable conclusions about causality can be reached. We computed the Bayes factor and posterior probability of C = 1 using expression (11). The Bayes factor is 53:21 and the resulting posterior probability is :982. Even in the presence of substantial uncertainty about the exact value of the prevalence parameter, the evidence in favor of causality in this example remains strong. Results are somewhat sensitive to the speci cation of the phenocopy rate , but the evidence in favor of causality is not questioned within a broad range of values. At = :1 the posterior probability is :987, while at = :3 it is :965.
Discussion
We propose an approach using Bayesian methods to statistically determine whether a missense mutation in an autosomal dominant disease gene is likely to be disease-causing.
Our method is particularly useful in evaluating common disease phenotypes, only a small proportion of which may be due to a known disease causing gene, such as hereditary breast cancer or familial colorectal cancer. This approach employs the testing of other a ected relatives for the missense mutation in pedigrees which have been identi ed through a proband with the missense mutation. The posterior probability that the mutation is disease causing is conditioned on the relationship of the relative to the proband, the frequency of the mutation, and the phenocopy rate of the disease. Because only a ected relatives are selected for genetic analysis, this method is e cient, from the perspective of conducting a study.
Because una ected relatives are not studied, this method avoids the pitfalls that relate to recruitment of such persons for research in the current genetic testing environment (Hubbard and Lewontin, 1996; Geller et al., 1997; Holtzman et al., 1997) .
However by limiting analysis only to families with at least two a ected relatives, there is a potential for biasing the conclusion in favor of causality, as the penetrance may in reality be lower than the sample indicates. This can be partially addressed by varying penetrance estimates in the computations. This design element also may a ect our results if there is a sizable proportion of families that have only one a ected person (proband) . If the una ected phenotypes in these families are due to reduced penetrance, the magnitude of the e ect for speci c mutations may only be empirically assessed by genotyping una ected relatives. This design modi cation, of course, engenders logistical issues in executing the study.
Another important consideration is the potential bias that may occur in the selection of a ected relatives for genotyping. Our approach assumes that inclusion in the study is unrelated to genotype. Ideally, any and all a ected biological relatives should be genotyped, but availability of DNA can be a ected by numerous factors (relatives who are deceased, unable or unwilling to participate). If availability for study is non-random for whatever reasons, this may have an e ect on the posterior probability, but the e ect would depend upon the nature of the selection bias.
We have shown that this method can be usefully applied to empiric data. We analyzed families identi ed through probands with the APC I1307K mutation (Laken et al., 1997) , in which 10/11 a ected relatives tested positive for the same mutation, including three second degree relatives. We found a :985 posterior probability that the APC I1307K mutation is causally related to the colorectal neoplasia in these families. In the case of BRCA1 R841W (Barker et al., 1996) , there were fewer families and persons studied, but we estimated a :836 posterior probability that this missense mutation may be causally related to breast cancer or ovarian cancer in these families.
These two examples contrast another challenge in interpreting missense mutations: plausible mechanism of disease causation engendered by the mutation (Ellsworth et al., 1997; Fearon, 1997) . In the case of APC I1307K, the T to A transversion in the APC gene results in an (A) 8 tract, which appears to engender an inherent instability of the gene, allowing deleterious mutations to occur in this critical gene during subsequent cell division (Laken et al., 1997) . In the case of BRCA1 R841W, however, it is di cult to posit a plausible mechanism because the function of the gene remains unclear. Our proposed method may provide additional evidence to support a disease-causing missense mutation in such cases.
That a missense mutation may have a plausible mechanism for causing disease can justify a more realistic estimate of the penetrance (whether higher or lower), while a missense mutation in a gene of unknown function may conservatively be justi ed to be lower.
There is a possibility, though remote, that the missense mutation may be in linkage disequilibrium with a "true" deleterious mutation elsewhere in the allele. When considering the way in which many missense mutations are identi ed through DNA sequencing, such a possibility would have been uncovered. In the case of our colon cancer example, Laken et al. (1997) reported that the APC I1307K bearing alleles in two carriers were fully sequenced and no other mutations were detected. This approach is predicated on the assumption that a single missense mutation has been singled out for particular attention on a priori grounds. Since disease genes may potentially be highly polymorphic, additional complications arise in interpreting the causality of polymorphisms that may come to attention because of their frequency in multiple case families, as such polymorphisms are more likely than randomly selected polymorphisms to appear to be causal, even if C=2 were true. A hierarchical Bayesian treatment of this problem might entail simultaneous consideration of all known polymorphisms, with additional parameters for variation in and p between polymorphisms. The model could include "prior covariates," such as the position in the gene or the nature of the particular amino acid substitution that results, whose e ects on penetrance are to be estimated empirically. Such an analysis is beyond the scope of this article, but similar methods have been applied in the treatment of multiple exposures problems in epidemiology (Greenland, 1993) and gene-environment interactions (Aragaki et al., 1997) .
The design approach of studying a ected relatives of a proband was employed by Swift et al. (1990) and applied by Athma et al. (1996) in a study of breast cancer risk in ataxia telangiectasia heterozygotes. This approach di ers from the method proposed here in a number of elements. Their design requires ascertainment of one a ected relative of an index carrier (who may not be a ected with the disease of interest) per family. Inference and testing are based on a large sample approximation to the con dence interval on the odds ratio of genotype given disease status. An important advantage of the Bayesian approach is that it is simple to derive inferences without having to rely on large sample approximations that could be inaccurate, and it is straightforward to incorporate uncertainty about unknown additional parameters, as discussed in the Appendix.
Finally, we have developed a simple program in S-Plus, shown in the Appendix, which provides computation of the Bayes factor and posterior probabilities in the rare allele case.
This basic approach can be extended to consider reduced penetrance with variable age at onset and errors in genetic testing. Development of these extensions is currently in progress.
Conclusions
The approach proposed here anticipates one of the outgrowths of the Human Genome Project and genetic disease research: a number of families that segregate common disease phenotypes may be identi ed to carry missense mutations of known disease causing genes. A concomitant problem in interpreting the signi cance of the missense mutations is determining whether they are disease causing or simple polymorphisms. We have developed a logistically e cient and computationally feasible approach that may more quickly help determine the importance of such mutations.
Appendix Unknown Penetrance and Prevalence
The derivation of the posterior probability of a causal e ect can be extended to the case of unknown penetrance and prevalence parameters. Within a Bayesian approach, this is carried out by replacing the xed values of and p with prior probability distributions re ecting information from prior studies or other biological evidence. The prior distribution on the unknown and p is denoted here by ( ; p) If the penetrance of similar mutation has been previously studied, published data can be used to specify an informative prior about .
Otherwise, an attractive option is to assume a priori that all values larger than ' are equally likely, leading to ( ) = 1=(1 ? '), ' < 1. Because the mutation may be responsible for a nonnegligible fraction of the overall cases, the assumption that ' is known also needs to be relaxed. Here we assume that the overall incidence is known. The overall incidence As in Section 2.2, under C = 1 it is natural to assume that > '. With this speci cation, then, we are testing a point null hypothesis against a composite alternative hypothesis. Berger and Delampady (1987) review the Bayesian approach to this problem and compare it to frequentist approaches . For a xed , a prior distribution on and p implies a prior distribution on '. Also ' < whenever < .
Under these assumptions, expression (1) remains the same, while expression (2) can be now interpreted as conditional on and p, that is: causal;k ( ; p) = Pfgjg 0k ; C = 1; ; pg = Pfg k jg 0k g n k ?n aa k ' n aa k 
and the posterior probability incorporating uncertainty about and p can be derived in the usual way as PfC = 1jDatag = OB=(1 + OB), where O is the prior odds in favor of C = 1.
Expression (11) is easily evaluated numerically using a Monte Carlo approach. To evaluate the numerator, it is su cient to generate a sample for the prior distribution ( ; p) and compute the average of the resulting values of Q K k=1 causal;k ( ; p). Expression (9) can be used to derive an a posteriori distribution on and p, conditional on C = 1: p( ; pjData; C = 1) = Q K k=1 causal;k ( ; p) ( ; p)
This provides a valid inference on the penetrance if it can be assumed that the selection mechanism, that is choosing families with at least one a ected relative and eliminating index cases, is not inducing a bias in the estimation of penetrance.
Rare Alleles
When the allele is rare, and there are no homozygous carriers in the sample, ignoring the dependence among relatives of the same proband and ignoring the possibility that there is more than one copy of the mutated allele in the same family have a limited impact on the nal answer. Expressions (1) and (2) can then be simpli ed considerably. It is interesting to study the form of these simpli ed expressions. All the N = P n k relatives can be considered to be approximately independent. For relative j, Let r j be the degree of relationship with the proband and h j be an indicator variable of whether relative j is a carrier or not. Then 
Each of the N terms is the ratio of the probability of the evidence under C = 2 to the probability of the evidence under C = 1, or weight of evidence against C = 2. For example, for a rst-degree relative the ratio is 2 =( + '), which is greater than one, if a carrier, and is 2'=( + '), which is smaller than one, if not a carrier.
In the unknown penetrance case, the expression for the Bayes factor becomes:
A function evaluating this expression using a Monte Carlo algorithm is provided below.
In the rare allele case it is simple to develop general-purpose functions for computing the Bayes factors and the posterior probability of causality. Here we present a function, written in the statistical package S-plus, that handles both the known and unknown penetrance case.
This function is available on the Internet site www.isds.duke.edu/~gp.
The input to the function are: the vector relations, with as many elements as there are relatives, and each element a 1,2, etc, for rst-, second-degree relatives etc; the vector genotypes, again with one element for each relative, either 0 if the relative is aa or 1 if the relative is Aa |use of the rare allele approximation is not recommended when there are homozygous relatives in the sample; the scalar prevalence, for the value of the prevalence if known; the Boolean variable unknown.prevalence, which can be set to T or F depending on whether the penetrance is known. If unknown.prevalence is set to T, the input value of prevalence is ignored; the integer MonteCarlo, specifying the number of Monte Carlo sample desired in evaluation the Bayes factor when the penetrance is unknown. 
